Single-Cell Genomics Pioneer Aviv Regev to Speak

Post Date: July 7, 2021 | Publish Date:

Genentech executive, founding co-chair of Human Cell Atlas, molecular circuitry expert to join Cincinnati Children’s speaker series

As Executive Vice President of Research and Early Development at Genentech, Aviv Regev, PhD, is responsible for the management of all aspects of Genentech’s drug discovery and drug development activities. She is a member of the Genentech Executive Committee and the expanded Corporate Executive Committee for Roche.

During her career, Regev has been a leader in deciphering molecular circuits that govern cells, tissues and organs in health and their malfunction in disease. Her lab has pioneered foundational experimental and computational methods in single-cell genomics, working toward greater understanding of the function of cells and tissues in health and disease, including autoimmune disease, inflammation and cancer.

Regev will speak at 2 pm, July 29, 2021, as part of the Envisioning Our Future For Children speaker series sponsored by the Cincinnati Children’s Research Foundation. The event is free and open to the public. Advance registration required.

Distinguished Career

Prior to Genentech, Regev served as Chair of the Faculty, Core Institute Member, founding director of the Klarman Cell Observatory, and member of the Executive Leadership Team of the Broad Institute of MIT and Harvard, as well as Professor of Biology at MIT and Investigator at the Howard Hughes Medical Institute. She is a founding co-chair of the Human Cell Atlas.

Regev has served on multiple corporate advisory, scientific advisory, and journal editorial boards, including the advisory committee to the National Human Genome Research Institute at the National Institutes of Health.

She is a member of the National Academy of Sciences and National Academy of Medicine, and she is also a Fellow of the International Society of Computational Biology.

Regev has a Ph.D. in computational biology and a Master of Science from Tel Aviv University.